IRMD vs. LIVN, WRBY, NVCR, LMAT, EYE, ENOV, CNMD, AORT, CDRE, and TNDM
Should you be buying iRadimed stock or one of its competitors? The main competitors of iRadimed include LivaNova (LIVN), Warby Parker (WRBY), NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Artivion (AORT), Cadre (CDRE), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry.
iRadimed vs. Its Competitors
iRadimed (NASDAQ:IRMD) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.
LivaNova has higher revenue and earnings than iRadimed. LivaNova is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
92.3% of iRadimed shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 36.8% of iRadimed shares are owned by company insiders. Comparatively, 0.3% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
iRadimed has a net margin of 26.33% compared to LivaNova's net margin of -17.41%. iRadimed's return on equity of 23.28% beat LivaNova's return on equity.
iRadimed currently has a consensus price target of $72.00, suggesting a potential upside of 18.99%. LivaNova has a consensus price target of $59.29, suggesting a potential upside of 29.59%. Given LivaNova's higher possible upside, analysts clearly believe LivaNova is more favorable than iRadimed.
In the previous week, iRadimed and iRadimed both had 2 articles in the media. iRadimed's average media sentiment score of 1.84 beat LivaNova's score of 0.63 indicating that iRadimed is being referred to more favorably in the media.
iRadimed has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.
Summary
iRadimed beats LivaNova on 9 of the 15 factors compared between the two stocks.
Get iRadimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iRadimed Competitors List
Related Companies and Tools
This page (NASDAQ:IRMD) was last updated on 7/2/2025 by MarketBeat.com Staff
Free IRMD Stock Alerts